Corporate Profile

Incyte’s mission is to become one of the leading global oncology companies.

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology.  For additional information on Incyte, please visit the Company’s website at

Recent News More >>
November 30, 2015Incyte’s Jakafi® (ruxolitinib) to be Featured in over 60 Abstracts at ASH Annual Meeting
Five-year COMFORT-II data in myelofibrosis and multiple ruxolitinib combination studies in MPNs and other hematologic malignancies accepted as oral and poster presentations WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 30, 2015-- Incyte Corporation (Nasdaq:INCY) announces that more than 60 abstracts featuring data from its ongoing clinical development program for Jakafi® (ruxolitinib) will be presented at the upcoming American Society of Hematology ... 
Printer Friendly Version
November 07, 2015Lilly and Incyte Announce Patients Treated with Baricitinib Demonstrated Significant Improvement in Signs and Symptoms of Rheumatoid Arthritis Compared with Methotrexate
INDIANAPOLIS, Nov. 7, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce detailed data from the pivotal phase 3 RA-BEGIN study, which show investigational baricitinib alone and in combination were superior to methotrexate monotherapy in helping patients achieve clinical remission. Findings will be shared at the American College of Rheumatology /Association of Rheumatology Health Professionals annual meeting in San Francisco, reveali... 
Printer Friendly Version
November 07, 2015Detailed Results Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis
Once-daily oral baricitinib significantly improved all seven components of ACR response versus injectable adalimumab Patient-reported pain, joint stiffness, fatigue and physical function scores significantly improved with baricitinib compared to adalimumab Detailed results from pivotal phase 3 study RA-BEAM presented at the American College of Rheumatology/Association of Rheumatology Health Professionals annual meeting PR Newswire, Indianapolis, November 7, 2015 Eli Lilly and... 
Printer Friendly Version

2014 Annual Report
2014 Annual Report Download Documentation

2014 10-K

Notice To Readers: Incyte's press releases, presentations and printed remarks are included on this Web site for historical purposes only. The information contained in these documents and webcasts should be considered accurate only as of the date of the relevant document or presentation. This information may change over time; therefore, visitors to this Web site should not assume that the information contained in these documents or presentations remains accurate at a later time. We do not have any current intention, and expressly disclaim any obligation, to supplement, update or revise any of the information in these documents or presentations.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.